Advertisement

Renal Sarcoma: A Population-Based Study

      Abstract

      Introduction

      Renal sarcomas are exceedingly rare and lack a prognostic stage classification. We thus aimed to investigate the contemporary clinicopathologic characteristics and outcomes of renal sarcomas at a national level.

      Methods

      : We utilized the Surveillance, Epidemiology, and End Results database to extract data on patients with renal sarcoma diagnosed between 2004-2015. We estimated median, 1-, 3-, and 5-year overall survival (OS) probabilities via Kaplan-Meier curves and used multivariable regression to compare OS between different patient groups.

      Results

      : We identified 365 patients; at diagnosis, 104 patients (28.5%) had stage I disease (T1N0M0), 133 patients (36.4%) patients had stage II disease (T2-4N0M0), and 117 patients (32.1%) patients had stage III disease (any T, N1 or M1). Median survival was 105 months (interquartile range [IQR], 29 – not reached) for stage I disease, 46 months (IQR 14-118 months) for stage II disease, 8 months (IQR 3-28 months) for stage III disease, and 32 months (IQR, 8-116 months) for the entire cohort. Patient age (HR for death [per year] 1.02, 95% CI 1.00-1.04), stage (II vs. I: HR 1.71, 95% CI 1.00-2.92; III vs. I: HR 4.93, 95% CI 2.68-9.05), grade (grade 3 vs. grade 1: 3.07, 95% CI 1.18-8.00; grade 4 vs. grade 1: HR 3.66, 95% CI 1.41-9.49), and possessing medical insurance (HR 0.40, 95% CI 0.16-0.94) were independently and significantly associated with overall survival. Performance of nephrectomy also trended towards independently improving OS (HR 0.23, 95% CI 0.05-1.09).

      Conclusion

      : A novel staging classification for renal sarcomas into a three-stage system based on TNM criteria produces distinct survival curves, although further studies are needed to robustly assess its validity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vogelzang NJ
        • Fremgen AM
        • Guinan PD
        • Chmiel JS
        • Sylvester JL
        • Sener SF.
        Primary renal sarcoma in adults. A natural history and management study by the American Cancer Society, Illinois Division.
        Cancer. 1993; 71: 804-810https://doi.org/10.1002/1097-0142(19930201)71:3<804::aid-cncr2820710324>3.0.co;2-a
        • Wang X
        • Xu R
        • Yan L
        • et al.
        Adult renal sarcoma: clinical features and survival in a series of patients treated at a high-volume institution.
        Urology. 2011; 77: 836-841https://doi.org/10.1016/j.urology.2010.09.028
        • Dotan ZA
        • Tal R
        • Golijanin D
        • et al.
        Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience.
        J Urol. 2006; 176: 2033-2039https://doi.org/10.1016/j.juro.2006.07.021
        • Samaratunga H
        • Delahunt B.
        Mesenchymal tumors of adult kidney.
        Semin Diagn Pathol. 2015; 32: 160-171https://doi.org/10.1053/j.semdp.2015.02.007
        • Moreira DM
        • Gershman B
        • Thompson RH
        • et al.
        Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study.
        Urol Oncol. 2015; 33 (505.e15-20)https://doi.org/10.1016/j.urolonc.2015.07.022
        • Vasquez Ciriaco S
        • García Espinoza JA
        • Garcia Pedro EE
        Primary leiomyosarcoma of kidney with metastasis to contralateral kidney. Case report.
        Interv Med Appl Sci. 2018; 10: 98-101https://doi.org/10.1556/1646.10.2018.12
        • Valente P
        • Macedo-Dias JA
        • Lobato C
        • Reis M
        • Pina F.
        Primary mesenchymal chondrosarcoma of the kidney: A case report and review of literature.
        J Cancer Res Ther. 2018; 14: 694-696https://doi.org/10.4103/0973-1482.172121
        • Fichera D
        • Luciano R
        • Nini A
        • et al.
        Clinical and pathological characteristics of a series of patients with newly diagnosed primary renal liposarcoma: natural history and effect on survival.
        Arch Esp Urol. 2018; 71: 555-558
        • Mantica G
        • Benelli A
        • Ackermann H
        • et al.
        Clinical and histopathological features of carcinosarcoma of the renal pelvis: a systematic review of a rare tumor.
        Minerva Urol Nefrol. 2019; 71: 121-126https://doi.org/10.23736/S0393-2249.18.03192-2
      1. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 8th edition 2018. Accessed November 1, 2021. https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx

      2. NCI Surveillance, Epidemiology, and End Results. SEER Incidence Data, 1973-2015. Accessed November 1, 2021. https://seer.cancer.gov/data/

      3. Surveillance Epidemiology and End Results Program. ICD-0-3 SEER Site/Histology Validation List. Accessed November 1, 2021. https://seer.cancer.gov/icd-o-3/sitetype.icdo3.20180117.pdf

      4. International Association of Cancer Registries. International Rules for Multiple Primary Cancers. Accessed November 1, 2021. http://www.iacr.com.fr/images/doc/MPrules_july2004.pdf

        • Ecker BL
        • Peters MG
        • McMillan MT
        • et al.
        Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma.
        Ann Surg Oncol. 2017; 24: 425-433https://doi.org/10.1245/s10434-016-5641-1
        • Keung EZ
        • Chiang Y-J
        • Voss RK
        • et al.
        Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma.
        Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2018; 44: 170-177https://doi.org/10.1016/j.ejso.2017.11.014
        • Nasioudis D
        • Alevizakos M
        • Chapman-Davis E
        • Witkin SS
        • Holcomb K.
        Rhabdomyosarcoma of the lower female genital tract: an analysis of 144 cases.
        Arch Gynecol Obstet. 2017; 296: 327-334https://doi.org/10.1007/s00404-017-4438-1
        • Heinze G
        • Wallisch C
        • Dunkler D.
        Variable selection - A review and recommendations for the practicing statistician.
        Biom J. 2018; 60: 431-449https://doi.org/10.1002/bimj.201700067
        • Novak M
        • Perhavec A
        • Maturen KE
        • Pavlovic Djokic S
        • Jereb S
        • Erzen D
        Leiomyosarcoma of the renal vein: analysis of outcome and prognostic factors in the world case series of 67 patients.
        Radiol Oncol. 2017; 51: 56-64https://doi.org/10.1515/raon-2016-0051
        • Bhangu AA
        • Beard JAS
        Grimer RJ. Should Soft Tissue Sarcomas be Treated at a Specialist Centre?.
        Sarcoma. 2004; 8: 1-6https://doi.org/10.1080/13577140410001679185
        • Hoven-Gondrie ML
        • Bastiaannet E
        • Ho VKY
        • et al.
        Worse Survival in Elderly Patients with Extremity Soft-Tissue Sarcoma.
        Ann Surg Oncol. 2016; 23: 2577-2585https://doi.org/10.1245/s10434-016-5158-7
        • Kelz RR
        • Gimotty PA
        • Polsky D
        • Norman S
        • Fraker D
        • DeMichele A.
        Morbidity and mortality of colorectal carcinoma surgery differs by insurance status.
        Cancer. 2004; 101: 2187-2194https://doi.org/10.1002/cncr.20624
        • Gaitanidis A
        • Alevizakos M
        • Tsalikidis C
        • Tsaroucha A
        • Simopoulos C
        • Pitiakoudis M.
        Refusal of Cancer-Directed Surgery by Breast Cancer Patients: Risk Factors and Survival Outcomes.
        Clin Breast Cancer. 2018; 18: e469-e476https://doi.org/10.1016/j.clbc.2017.07.010
        • Capitanio U
        • Montorsi F.
        Renal cancer.
        Lancet (London, England). 2016; 387: 894-906https://doi.org/10.1016/S0140-6736(15)00046-X
        • Urasaki T
        • Nakano K
        • Tomomatsu J
        • et al.
        Adult genitourinary sarcoma: The era of optional chemotherapeutic agents for soft tissue sarcoma.
        Int J Urol Off J Japanese Urol Assoc. 2021; 28: 91-97https://doi.org/10.1111/iju.14417
        • Raja A
        • Ratnagiri R
        • Mss K
        • Malik K
        • Menon AR.
        Primary Renal Synovial Sarcoma Case Series: Clinical Profile and Management of a Rare Entity.
        Urol Int. 2022; 106: 426-428https://doi.org/10.1159/000520223